

Amendments to the Claims under Revised 37 C.F.R. § 1.121

Claim 1 (currently amended): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is encoded by a nucleic acid molecule comprising the nucleotide sequence as set forth in ~~any of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, residues 4 through 549 of SEQ ID NO: 9, residues 4 through 519 of SEQ ID NO: 15, or residues 4 through 516 of SEQ ID NO: 19.~~

Claims 2-22 (cancelled).

Claim 23 (currently amended): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide comprises the amino acid sequence as set forth in ~~any of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, residues 2 through 183 of SEQ ID NO: 10, residues 2 through 173 of SEQ ID NO: 16, or residues 2 through 172 of SEQ ID NO: 20.~~

Claims 24-40 (cancelled).

Claim 41 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 4.

Claim 42 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective

amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is nonglycosylated or is glycosylated by a CHO cell, and wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 4 and an amino-terminal methionine.

Claims 43-44 (cancelled).

Claim 45 (currently amended): The method of ~~either~~ Claims 15 or 23, wherein said polypeptide has at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and the carboxyl-terminus.

Claim 46 (original): The method of Claim 45, wherein said polypeptide has at least one additional amino acid at the amino-terminus.

Claim 47 (original): The method of Claim 46, wherein said polypeptide has a methionine at the amino-terminus.

Claim 48 (original): The method of Claim 45, wherein said polypeptide has at least one additional amino acid at the carboxyl-terminus.

Claim 49 (cancelled).

Claim 50 (currently amended): The method of ~~any of either~~ Claim[[s]] 1, 15, or 23, wherein said polypeptide is chemically derivatized.

Claim 51 (currently amended): The polypeptide of any of Claims 1, 14, 15, 23, 36, 37, 41, or 42, 43, 44, or 49, wherein said polypeptide is not glycosylated.

Claim 52 (currently amended): The polypeptide of any of Claims 1, 14, 15, 23, 36, 37, 41, or 42, 43, 44, or 49, wherein said polypeptide is glycosylated.

Claim 53 (original): The polypeptide of Claim 52, wherein said polypeptide is glycosylated by a CHO cell.

Claim 54 (currently amended): The method of ~~any of~~ either Claim[[s]] 1, 15, or 23, wherein said recombinant polypeptide is expressed in a cultured cell *in vitro* and said recombinant polypeptide is isolated therefrom.

Claim 55 (original): The method of Claim 54, wherein the cultured cell is a non-human cell.

Claim 56 (previously presented): The method of Claim 55, wherein the non-human cell is a prokaryotic cell.

Claim 57 (original): The method of Claim 56, wherein the prokaryotic cell is *Escherichia coli*.

Claim 58 (previously presented): The method of Claim 55, wherein the non-human cell is a eukaryotic cell.

Claim 59 (original): The method of Claim 58, wherein the eukaryotic cell is a mammalian cell.

Claim 60 (original): The method of Claim 59, wherein the mammalian cell is a Chinese Hamster Ovary cell or a COS cell.

Claim 61 (original): The method of Claim 54, wherein the polypeptide is glycosylated.

Claim 62 (original): The method of Claim 54, wherein the polypeptide is not glycosylated.